Cite
HARVARD Citation
Rittmeyer, A. et al. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 389 (10066), pp. 255-265. [Online].